C. Service-de-reanimation-medicale, R. Hopital, and A. Poincare, 3 Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, 1161 21st Avenue South T1218 MCN, Nashville, TN 37232-2650, USA. 4 Section of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, Charing Cross Hospital, Fulham Palace Road The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, 104 Bd Raymond Poincare. 8 Sirius Genomics Inc, 603-1125 Howe St, pp.166-1081, 2010.

D. Angus, W. Linde-zwirble, J. Lidicker, G. Clermont, J. Carcillo et al., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care, Critical Care Medicine, vol.29, issue.7, pp.291303-1310, 2001.
DOI : 10.1097/00003246-200107000-00002

A. Davies, C. Green, and J. Hutton, Severe sepsis: a European estimate of the burden of disease in ICU [oral presentation abstract from 14th, Annual Congress of the European Society of Intensive Care Medicine, pp.27-284, 2001.

G. Martin, D. Mannino, S. Eaton, and M. Moss, The Epidemiology of Sepsis in the United States from 1979 through 2000, New England Journal of Medicine, vol.348, issue.16, pp.1546-1554, 2000.
DOI : 10.1056/NEJMoa022139

G. Bernard, J. Vincent, P. Laterre, S. Larosa, J. Dhainaut et al., Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis, N Engl J Med, issue.10, pp.344699-709, 2001.

J. Siegel, Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis, New England Journal of Medicine, vol.347, issue.13, pp.1030-1034, 2002.
DOI : 10.1056/NEJMsb021512

D. Food and . Administration, CDER 2001 meeting documents. Transcript of Anti-Infective Drugs Advisory Committee Meeting Available from http, 2001.

E. Abraham, P. Laterre, R. Garg, H. Levy, D. Talwar et al., Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death, N Engl J Med, issue.13, pp.3531332-1341, 2005.

S. Nadel, B. Goldstein, M. Williams, H. Dalton, M. Peters et al., Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective (RESOLVE) Study Group, Lancet, issue.9564, pp.369836-843, 2007.

J. Dhainaut, International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy, Current Medical Research and Opinion, vol.24, issue.4, pp.1187-1197, 2008.
DOI : 10.1185/030079908X280563

D. Food and . Administration, Approval Letter, BLA#125029, Drotrecogin alfa (activated), Xigris.; Accessed 10, 2001.

A. European-medicines, Marketing authorization. European public assessment report, Drotrecogin alfa (activated), Xigris, 2002.

S. Finfer, V. Ranieri, B. Thompson, P. Barie, J. Dhainaut et al., Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock, Intensive Care Med, issue.11, pp.341935-1947, 2008.

L. Wang, H. Mcleod, and R. Weinshilboum, Genomics and drug response, N Engl J Med, vol.364, pp.1144-1153, 2011.

J. Russell, K. Walley, J. Singer, A. Gordon, P. Hébert et al., Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock, New England Journal of Medicine, vol.358, issue.9, pp.877-887, 2008.
DOI : 10.1056/NEJMoa067373

L. Cardon and J. Bell, Association study designs for complex diseases, Nature Reviews Genetics, vol.2, issue.2, pp.91-99, 2001.
DOI : 10.1038/35052543

C. Touchberry, I. Bales, J. Stone, T. Rohrberg, N. Parelkar et al., Phosphatidylinositol 3,5-bisphosphanate (PI(3,5)P2) potentiates cardiac contractility via activation of the ryanodine receptor, J Biol Chem, issue.51, pp.28540312-40321, 2010.

S. Sahara, M. Aoto, Y. Eguchi, N. Imamoto, Y. Yoneda et al., Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation, Nature, vol.401, issue.6749, pp.168-173, 1999.

K. Rowan, C. Welch, E. North, and D. Harrison, Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care, p.58, 2008.

G. Bertolini, C. Rossi, A. Anghileri, S. Livigni, A. Addis et al., Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a??nationwide survey, Intensive Care Medicine, vol.29, issue.3, pp.426-434, 2007.
DOI : 10.1007/s00134-007-0554-x

A. Wheeler, J. Steingrub, G. Schmidt, P. Sanchez, J. Jacobi et al., A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial*, Critical Care Medicine, vol.36, issue.1, pp.14-23, 2008.
DOI : 10.1097/01.CCM.0000298309.73776.CB

S. Kanji, M. Perreault, C. Chant, D. Williamson, and L. Burry, Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a??Canadian multicenter observational study, Intensive Care Medicine, vol.31, issue.12 Suppl, pp.517-523, 2007.
DOI : 10.1007/s00134-007-0555-9

S. Ridley, A. Lwin, D. Wyncoll, S. Lippett, D. Watson et al., Drotrecogin alfa (activated), European Journal of Anaesthesiology, vol.25, issue.3, pp.211-216, 2008.
DOI : 10.1017/S0265021507002992

J. Vincent, P. Laterre, J. Decruyenaere, H. Spapen, J. Raemaekers et al., A REGISTRY OF PATIENTS TREATED WITH DROTRECOGIN ALFA (ACTIVATED) IN BELGIAN INTENSIVE CARE UNITS - AN OBSERVATIONAL STUDY, Acta Clinica Belgica, vol.27, issue.284, pp.25-30, 2008.
DOI : 10.1007/s00134-004-2157-0

O. Miettinen, Individual Matching with Multiple Controls in the Case of All-or-None Responses, Biometrics, vol.25, issue.2, pp.339-355, 1969.
DOI : 10.2307/2528794

K. Ming and P. Rosenbaum, Substantial Gains in Bias Reduction from Matching with a Variable Number of Controls, Biometrics, vol.27, issue.1, pp.118-124, 2000.
DOI : 10.1111/j.0006-341X.2000.00118.x

P. Rosenbaum and D. Rubin, Constructing a control group using multivariate matched sampling methods that incorporate the propensity score, Am Stat, vol.39, issue.1, pp.33-38, 1985.

E. Ely, P. Laterre, D. Angus, J. Helterbrand, H. Levy et al., Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis, Critical Care Medicine, vol.31, issue.1, pp.3112-3131, 2003.
DOI : 10.1097/00003246-200301000-00002

G. Rubenfeld, E. Caldwell, E. Peabody, J. Weaver, D. Martin et al., Incidence and Outcomes of Acute Lung Injury, New England Journal of Medicine, vol.353, issue.16, pp.1685-1693, 2005.
DOI : 10.1056/NEJMoa050333

C. Cooke, C. Shah, R. Gallop, S. Bellamy, M. Ancukiewicz et al., for the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: A simple clinical predictive index for objective estimates of mortality in acute lung injury, Crit Care Med, issue.16, pp.371913-1920, 2009.

M. Esson and R. Schrier, Diagnosis and Treatment of Acute Tubular Necrosis, Annals of Internal Medicine, vol.137, issue.9, pp.744-752, 2002.
DOI : 10.7326/0003-4819-137-9-200211050-00010

R. Schrier and W. Wang, Acute Renal Failure and Sepsis, New England Journal of Medicine, vol.351, issue.2, pp.159-169, 2004.
DOI : 10.1056/NEJMra032401

S. Vanderschueren, D. Weerdt, A. Malbrain, M. Vankersschaever, D. Frans et al., Thrombocytopenia and prognosis in intensive care, Critical Care Medicine, vol.28, issue.6, pp.1871-1876, 2000.
DOI : 10.1097/00003246-200006000-00031

J. Vincent, A. Yagushi, and O. Pradier, Platelet function in sepsis, Critical Care Medicine, vol.30, issue.Supplement, pp.313-317, 2002.
DOI : 10.1097/00003246-200205001-00022

W. Knaus, E. Draper, D. Wagner, and J. Zimmerman, APACHE II, Critical Care Medicine, vol.13, issue.10, pp.818-829, 1985.
DOI : 10.1097/00003246-198510000-00009

L. Gall, J. Lemeshow, S. Saulnier, and F. , A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study, JAMA: The Journal of the American Medical Association, vol.270, issue.24, pp.2957-2963, 1993.
DOI : 10.1001/jama.1993.03510240069035

P. Laterre, G. Garber, H. Levy, R. Wunderink, G. Kinasewitz et al., Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*, Critical Care Medicine, vol.33, issue.5, pp.952-961, 2005.
DOI : 10.1097/01.CCM.0000162381.24074.D7

W. Cochran and D. Rubin, Controlling Bias in Observational Studies: A Review, Indian J Stat, vol.35, issue.4, pp.417-446, 1973.
DOI : 10.1017/CBO9780511810725.005

X. Gu and P. Rosenbaum, Comparison of multivariate matching methods: structures, distances, and algorithms, J Computational Graphical Statistics, vol.4, pp.405-420, 1993.

P. Austin, A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003, Statistics in Medicine, vol.26, issue.1, pp.2037-2049, 1996.
DOI : 10.1002/sim.3150

. Kosoyr, . Nassirr, . Tianc, . Whitepa, . Butlerlm et al., Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America, Human Mutation, vol.118, issue.1, pp.69-78, 2009.
DOI : 10.1002/humu.20822

R. Nassir, R. Kosoy, C. Tian, P. White, L. Butler et al., An ancestry informative marker set for determining continental origin: validation and extension using human genome diversity panels, BMC Genetics, vol.10, issue.1, p.39, 2009.
DOI : 10.1186/1471-2156-10-39

URL : http://doi.org/10.1186/1471-2156-10-39